Trials / Completed
CompletedNCT01693692
Phase 2 Study of TD-9855 to Treat Fibromyalgia
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of TD-9855 in Patients With Fibromyalgia (FM)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 392 (actual)
- Sponsor
- Theravance Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study study is to determine whether TD-9855 is effective in treating patients with fibromyalgia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-9855 Group 1 | |
| DRUG | TD-9855 Group 2 | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2014-01-01
- Completion
- 2014-04-01
- First posted
- 2012-09-26
- Last updated
- 2022-03-04
- Results posted
- 2022-03-04
Locations
34 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01693692. Inclusion in this directory is not an endorsement.